Cabaletta Bio, Inc. (CABA)
| Market Cap | 316.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -167.86M |
| Shares Out | 111.32M |
| EPS (ttm) | -2.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,771,587 |
| Open | 2.900 |
| Previous Close | 2.910 |
| Day's Range | 2.790 - 2.930 |
| 52-Week Range | 1.110 - 3.780 |
| Beta | 3.29 |
| Analysts | Strong Buy |
| Price Target | 14.50 (+409.67%) |
| Earnings Date | May 14, 2026 |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclero... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CABA stock is "Strong Buy." The 12-month stock price target is $14.5, which is an increase of 409.67% from the latest price.
News
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry Initial t...
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply agreemen...
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed sp...
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.'s (“Cabaletta Bio” or “Cabaletta...
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option
Cabaletta Bio Transcript: TD Cowen 46th Annual Health Care Conference
Key clinical milestones include pivotal myositis trial enrollment, upcoming durability data in pemphigus and lupus, and phase I/II results in multiple autoimmune indications. Automated manufacturing with Cellares enables scalable, cost-effective production, while a favorable safety profile and no preconditioning regimen could transform market adoption.
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell the...
Cabaletta Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The summit highlighted progress in pivotal myositis trials, advances in automated manufacturing, and a strong safety profile enabling outpatient treatment. Regulatory alignment supports single-arm trials, and the commercial model leverages automation for scalability and cost efficiency.
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell the...
Cabaletta Bio Announces 2026 Strategic Priorities
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio's (Nasdaq: CABA) investigational CAR ...
Cabaletta Bio Transcript: Citi Annual Global Healthcare Conference 2025
Rese-cel is advancing through pivotal trials with strong efficacy and safety data, enabling outpatient administration and scalable manufacturing. The commercial strategy leverages a large clinical footprint, automated production, and a compelling value proposition for payers and patients. Early 2026 and 2027 are key milestones for launch and scalability.
Cabaletta Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference
Recent clinical data in myositis, scleroderma, and lupus support single-arm pivotal trials with strong FDA alignment. Outpatient administration and a younger, privately insured patient base create a favorable commercial model, while manufacturing and supply strategies are set for broad, efficient market entry.
Cabaletta Bio Transcript: Jefferies London Healthcare Conference 2025
Autologous CAR-T therapies are leading in autoimmune disease, with strong efficacy and safety data. The myositis program is advancing toward a 2027 BLA, leveraging outpatient administration and a broad indication strategy for commercial viability.
Cabaletta Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Transformative clinical data in multiple autoimmune diseases has led to strong FDA alignment for pivotal trials, with myositis enrollment starting this year and systemic sclerosis and lupus soon to follow. A no preconditioning approach may enable single-infusion outpatient therapy, while the commercial strategy focuses on rapid expansion and cost efficiency.
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient...
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS re...
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Ca...
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators s...
Cabaletta Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Multiple pivotal data readouts for Rese-cel in myositis, lupus, scleroderma, and myasthenia gravis are expected in October, with the potential for first-to-market status in myositis and a significant competitive edge if no preconditioning proves effective. Robust enrollment and strong physician interest support an accelerated regulatory path.
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis –
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Pr...
Cabaletta Bio Announces Pricing of Public Offering of Securities
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first ...